|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2002-1-21
|
|
pubmed:abstractText |
Ecteinascidin 743 (ET-743) is a novel, marine-derived anticancer agent currently under clinical development for the treatment of solid tumors. The aim of this study was to develop and validate limited sampling strategies for the prediction of ET-743 clearance in phase II studies, using two techniques: the stepwise linear regression approach and the Bayesian estimation approach.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Dec
|
|
pubmed:issn |
0344-5704
|
|
pubmed:author |
pubmed-author:BeijnenJ HJH,
pubmed-author:BraisHH,
pubmed-author:CvitkovicEE,
pubmed-author:GuzmanCC,
pubmed-author:HillebrandM JMJ,
pubmed-author:JimenoJ MJM,
pubmed-author:López-LázaroLL,
pubmed-author:Math?tR ARA,
pubmed-author:MissetJ LJL,
pubmed-author:RosingHH,
pubmed-author:SchellensJ HJH,
pubmed-author:TaammaAA,
pubmed-author:van KesterenCC
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
48
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
459-66
|
|
pubmed:dateRevised |
2008-11-29
|
|
pubmed:meshHeading |
pubmed-meshheading:11800026-Adult,
pubmed-meshheading:11800026-Antineoplastic Agents, Alkylating,
pubmed-meshheading:11800026-Bayes Theorem,
pubmed-meshheading:11800026-Blood Specimen Collection,
pubmed-meshheading:11800026-Dioxoles,
pubmed-meshheading:11800026-Dose-Response Relationship, Drug,
pubmed-meshheading:11800026-Forecasting,
pubmed-meshheading:11800026-Half-Life,
pubmed-meshheading:11800026-Humans,
pubmed-meshheading:11800026-Infusions, Intravenous,
pubmed-meshheading:11800026-Isoquinolines,
pubmed-meshheading:11800026-Models, Theoretical,
pubmed-meshheading:11800026-Regression Analysis,
pubmed-meshheading:11800026-Tetrahydroisoquinolines,
pubmed-meshheading:11800026-Time Factors
|
|
pubmed:year |
2001
|
|
pubmed:articleTitle |
A comparison of limited sampling strategies for prediction of Ecteinascidin 743 clearance when administered as a 24-h infusion.
|
|
pubmed:affiliation |
Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute/Slotervaart Hospital, Amsterdam. APCKS@SLZ.NL
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Validation Studies
|
